Manohar P Ram, Rather Tanveer A, Khan Shoukat H, Malik Dharmender
Department of Nuclear Medicine, SKIMS, Srinagar, Jammu and Kashmir, India.
World J Nucl Med. 2017 Jan-Mar;16(1):39-44. doi: 10.4103/1450-1147.181153.
The purpose of the study is to find out the overall incidence of superscan among different type of cancers, causes of superscan and its relationship with other parameters such as age, sex, duration of disease, and serum alkaline phosphatase (ALP) levels. This was a retro-prospective study. Records of all previous bone scans and reported patients of superscan were re-evaluated retrospectively. Patients who were diagnosed as having superscan in the preceding 3 years with confirmed histopathological diagnosis were included in the retrospective group. In the prospective group, all the patients who were reported to have superscan appearance over the past 2 years of prospective period were included. Total of 6027 bone scans were examined in a 5-year period and out of which 80 cases were diagnosed as superscan. The overall incidence of superscan in different type of cancers was 1.3% (80/6027). Prostate cancer (46/80) was the most common cause of superscan appearance followed by breast cancer (10/80). Out of 6027 patients referred for bone scan, 307 patients had prostate cancer on histopathological examination. Out of 307 patients with prostate cancer, 46 had superscan appearance. Incidence of superscan in prostate cancer was 14.98% (46/307), and 71.73% (33/46) prostate cancer patients with superscan had Gleason score of 8 and above 8 with mean serum prostate-specific antigen level was 178.42 ng/ml in symptomatic patients and 122 ng/ml in asymptomatic patients. Out of all patients with superscan, 71 patients (88.7%) had elevated serum ALP levels. Overall incidence of superscan in our study was 1.3% in different type of cancer patients, and the most common cause of superscan appearance was prostate cancer. Incidence of superscan appearance in prostatic cancer patients was 14.98%.
本研究的目的是找出不同类型癌症中超扫描的总体发生率、超扫描的原因及其与年龄、性别、疾病持续时间和血清碱性磷酸酶（ALP）水平等其他参数的关系。这是一项回顾性-前瞻性研究。对所有既往骨扫描记录和报告的超扫描患者进行回顾性重新评估。回顾性组纳入了在过去3年中被诊断为超扫描且组织病理学诊断确诊的患者。在前瞻性组中，纳入了在前瞻性观察期过去2年中报告有超扫描表现的所有患者。在5年期间共检查了6027例骨扫描，其中80例被诊断为超扫描。不同类型癌症中超扫描的总体发生率为1.3%（80/6027）。前列腺癌（46/80）是超扫描表现最常见的原因，其次是乳腺癌（10/80）。在6027例接受骨扫描的患者中，经组织病理学检查有307例患有前列腺癌。在307例前列腺癌患者中，46例有超扫描表现。前列腺癌中超扫描的发生率为14.98%（46/307），超扫描的前列腺癌患者中71.73%（33/46）的Gleason评分为8分及以上8分，有症状患者的平均血清前列腺特异性抗原水平为178.42 ng/ml，无症状患者为122 ng/ml。在所有超扫描患者中，71例（88.7%）血清ALP水平升高。在我们的研究中，不同类型癌症患者中超扫描的总体发生率为1.3%，超扫描表现最常见的原因是前列腺癌。前列腺癌患者中超扫描表现的发生率为14.98%。
